Dear experts,
As we dig into scientific papers investigating drug delivery systems using various nano carriers, one thing that attracts attention is the strategies the authors exploited to mask carrier toxicity. One of the well-known approach is to employ molecules with negative charges to mask positive surface charges in an attempt to reduce interaction of the delivery system with negatively charged components such as blood cells and proteins. However, when the surface charge reduced, the first victim will be cellular uptake of the nano carriers. So here comes the dilemma.
In fact, reducing surface charge of the delivery system in order to reduce toxicity is not even an approach! It makes a completely different delivery system with significantly reduced cellular uptake.
Has come the time to change our strategy yet?
At least lead researchers can guide naive ones to orient their studies better.
What do you think?